What are the effects of intra‑articular corticosteroid injection on acute gout?

Intra-articular Corticosteroid Injection for Acute Gout

Intra-articular corticosteroid injections are a reasonable treatment option for acute gout, particularly when systemic therapy is contraindicated, though they should be considered after oral/systemic corticosteroids, NSAIDs, or colchicine as first-line options.

Evidence Base and Limitations

The evidence for intra-articular corticosteroids specifically in acute gout is surprisingly limited. A 2013 Cochrane review found no randomized controlled trials evaluating intra-articular glucocorticoids for acute gout 1. This represents a significant evidence gap for a commonly used intervention.

However, the American College of Physicians 2017 guideline recommends corticosteroids (generally systemic) as first-line therapy for acute gout, noting they are as effective as NSAIDs with fewer adverse effects 2. The guideline emphasizes that corticosteroids should be considered as first-line therapy in patients without contraindications because they are generally safer and a low-cost treatment option 2.

Clinical Reasoning for Intra-articular Use

While direct evidence is lacking, the rationale for intra-articular use is sound:

• Systemic corticosteroids have proven anti-inflammatory effects and were equivalent to NSAIDs in 6 RCTs for acute gout 2
• Intra-articular corticosteroids are effective in other inflammatory arthritides (osteoarthritis, rheumatoid arthritis), and these results may be generalizable to acute gout 1
• The approach is particularly valuable when systemic anti-inflammatory drugs are contraindicated due to renal disease, heart failure, cirrhosis, or gastrointestinal concerns 2

When to Consider Intra-articular Injection

Use intra-articular corticosteroids for acute gout when:

• Monoarticular involvement (single joint affected)
• Contraindications exist to oral corticosteroids, NSAIDs, or colchicine
• Patient has multiple comorbidities making systemic therapy risky
• Rapid local control is needed in a single problematic joint

Safety Considerations

The 2021 EULAR recommendations for intra-articular therapies provide important safety guidance 3:

• Avoid overuse of the injected joint for 24 hours, but immobilization is discouraged
• Diabetic patients should monitor glucose levels particularly days 1-3 post-injection, as transient hyperglycemia can occur
• Wait at least 3 months before joint replacement surgery if injection is performed
• General practice suggests avoiding more than 3-4 glucocorticoid injections in the same joint per year 3

Common Pitfalls

• Do not assume intra-articular injection is superior to systemic therapy - no evidence supports this, and systemic corticosteroids remain first-line
• Do not use in polyarticular gout - systemic therapy is more appropriate
• Do not inject prosthetic joints routinely - this should only be considered after consultation with orthopedic surgery and strict infection screening 3
• Be aware that while rare, adverse joint events including accelerated OA progression have been reported with repeated corticosteroid injections 4

Practical Approach

For acute monoarticular gout:

1. First consider: oral corticosteroids (prednisolone 35 mg for 5 days), NSAIDs, or low-dose colchicine 2
2. If systemic therapy contraindicated: intra-articular corticosteroid injection is reasonable
3. Use triamcinolone or equivalent glucocorticoid preparation
4. Advise 24-hour activity modification without strict immobilization
5. Monitor glucose in diabetic patients for 3 days post-injection

The lack of RCT evidence for this specific indication means clinical judgment based on extrapolation from systemic corticosteroid efficacy and intra-articular use in other conditions guides practice 1.